These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24098634)

  • 1. Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
    Reyskens KM; Fisher TL; Schisler JC; O'Connor WG; Rogers AB; Willis MS; Planesse C; Boyer F; Rondeau P; Bourdon E; Essop MF
    PLoS One; 2013; 8(9):e73347. PubMed ID: 24098634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system.
    Reyskens KM; Essop MF
    Biochim Biophys Acta; 2014 Feb; 1842(2):256-68. PubMed ID: 24275553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2003 May; 168(1):107-13. PubMed ID: 12732393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
    Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.
    Marima R; Hull R; Dlamini Z; Penny C
    Biomed Pharmacother; 2020 Dec; 132():110829. PubMed ID: 33059259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
    Pao VY; Lee GA; Taylor S; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2010 Jan; 24(2):265-70. PubMed ID: 19890203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
    Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
    AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
    Hill A; Sawyer W; Gazzard B
    HIV Clin Trials; 2009; 10(1):1-12. PubMed ID: 19362991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.
    Croxtall JD; Perry CM
    Drugs; 2010 Oct; 70(14):1885-915. PubMed ID: 20836579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
    Wu X; Sun L; Zha W; Studer E; Gurley E; Chen L; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Wang G; Chen J; Wang JY; Zhou H
    Gastroenterology; 2010 Jan; 138(1):197-209. PubMed ID: 19732776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.
    Richmond SR; Carper MJ; Lei X; Zhang S; Yarasheski KE; Ramanadham S
    Biochim Biophys Acta; 2010 May; 1801(5):559-66. PubMed ID: 20117238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.